eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img

CHOOSE ELIQUIS (apixaban) FOR YOUR PATIENTS
WITH DVT / PE

ELIQUIS – AN ORAL, DIRECT FACTOR XA INHIBITOR – IS INDICATED FOR:

  • Treatment of DVT and PE, and prevention of recurrent DVT and PE in adults1

  • Prevention of VTE in adult patients who have undergone elective knee or hip replacement surgery1

Explore data for ELIQUIS in DVT / PE treatment and prevention

Treatment of DVT / PE

In the AMPLIFY clinical trial, ELIQUIS demonstrated both comparable efficacy with significantly less major bleeding vs. enoxaparin / warfarin in the treatment of DVT / PE.2

Explore data from the AMPLIFY trial.

Extended treatment for prevention of recurrent DVT / PE

In the AMPLIFY-EXT clinical trial, ELIQUIS demonstrated superior efficacy with a comparable major bleeding profile vs. placebo for patients with DVT / PE.3

Explore data from the AMPLIFY-EXT trial.

Explore data for ELIQUIS in VTE prophylaxis after hip or knee surgery

In the ADVANCE-2 clinical trial, ELIQUIS demonstrated superior efficacy and a comparable bleeding rate
vs. enoxaparin in patients receiving treatment for prevention of VTE recurrence after elective total knee replacement surgery.4

In the ADVANCE-3 clinical trial, ELIQUIS demonstrated superior efficacy and a comparable bleeding rate
vs. enoxaparin in patients receiving treatment for prevention of VTE recurrence after elective total hip replacement surgery.5

Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

ADVANCE-2 = Apixaban Versus Enoxaparin for Thromboprophylaxis After Knee Replacement   
ADVANCE-3 = Apixaban Dosed Orally Versus Anticoagulation with Injectable Enoxaparin to Prevent Venous Thromboembolism   
AMPLIFY = Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line   
AMPLIFY-EXT = Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy–Extended Treatment   
DVT = Deep Vein Thrombosis   
NVAF = Non-Valvular Atrial Fibrillation   
PE = Pulmonary Embolism   
VTE = Venous Thromboembolic Events   

References

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. Agnelli G et al. N Engl J Med 2013; 369: 799–808.
  3. Agnelli G et al. N Engl J Med 2013; 368: 699–708.
  4. Lassen MR et al. Lancet 2010; 375: 807–815.
  5. Lassen MR et al. N Engl J Med 2010; 363: 2487–2498.